Bruker Corporation announced on May 14, 2025, that it has reached a final settlement with 10x Genomics to resolve their patent disputes. This agreement includes global patent cross-license agreements between the two companies.
As a result of the settlement, all ongoing lawsuits and administrative proceedings filed by both companies in various countries, including the United States, Germany, and before the European Unified Patent Court, will be withdrawn.
Mark R. Munch, President of the Bruker Nano Group, stated that the settlement is a positive outcome for the scientific community, allowing them to continue using Bruker’s CosMx® and GeoMx® spatial biology platforms without litigation concerns. This resolution removes a significant legal and financial distraction for Bruker.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.